Dr. George Allen is an Associate Professor and Chair of the Department of Pharmacy Practice at the College of Pharmacy at UNE. Dr. Allen earned his Doctor of Pharmacy degree from the Massachusetts College of Pharmacy and Allied Health Sciences in 1998. Dr. Allen then completed a Pharmacy Practice Residency at the University of Washington in Seattle, WA, and a Fellowship in Infectious Diseases Pharmacotherapy at Wayne State University in Detroit, MI. As a postdoctoral fellow, Dr. Allen performed laboratory-based research examining induction of bacterial resistance by a variety of antimicrobials. Before joining UNE in 2010, Dr. Allen was a member of the faculty at the Oregon State University College of Pharmacy in Portland, OR, where he continued his in vitro research and participated in didactic and experiential education of Doctor of Pharmacy students.
Massachusetts College of Pharmacy and Allied Health Sciences
University of New Hampshire
Infectious Diseases Pharmacotherapy
Wayne State University College of Pharmacy and Allied Health
University of Washington and Harborview Medical Centers
Pharmacotherapy of infectious diseases
Dr. Allen's research focuses on investigations of the pharmacodynamics of antimicrobial resistance. He uses in vitro modeling techniques that allow evaluation of the effects of varying antimicrobial exposures on the development of resistance. The majority of Dr. Allen's current work consists of studies of two unique measures of antimicrobial activity, the mutant prevention concentration and mutant selection window. This work is performed using a variety of clinically important bacterial species, including Neisseria gonorrhoeae, Klebsiella pneumoniae, Salmonella enterica, and Shigella flexneri, with most research focusing on the fluoroquinolone antimicrobials. Broadly speaking, Dr. Allen's work is designed to determine those antimicrobials (as well as the optimal doses of said antimicrobials) that will best prevent the emergence of bacterial resistance in the laboratory and, potentially, in clinical settings.
Allen GP, Harris KA. In vitro resistance selection in Shigella flexneri by azithromycin, ceftriaxone, ciprofloxacin, levofloxacin, and moxifloxacin. Antimicrobial Agents and Chemotherapy 2017;61:e00082-17.
Allen GP, Moore WM, *Moser LR, Neill KK, Sambamoorthi U, Bell HS. The role of servant leadership and transformational leadership in academic pharmacy. American Journal of Pharmaceutical Education 2016;80:Article 113.
McGregor JC, Hartung DM, Allen GP, Taplitz RA, Traver R, Tong T, Bearden DT. Risk factors associated with linezolid non-susceptible enterococcal infections. American Journal of Infection Control 2012;40:886-7.
Allen GP, Deshpande LM. Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin, and trimethoprim/sulfamethoxazole against community-associated meticillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 2010;35:45-9.
Allen GP, Hankins CD. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy 2009;64:359-63.
Allen GP, Bierman BC. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium. International Journal of Antimicrobial Agents 2009;34:21-4.
McGregor JC, Allen GP, Bearden DT. Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Therapeutics and Clinical Risk Management 2008;4:843-53.
Bearden DT, Allen GP, Christensen JM. Comparative in vitro activities of topical wound care products against community-associated methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 2008;62:769-72.
Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. International Journal of Antimicrobial Agents 2004;24:150-60.
Bearden DT, Allen GP. Impact of antimicrobial control programs on patient outcomes: pharmacy perspective. Disease Management and Health Outcomes 2003;11:723-36.
Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 2003;47:2606-14.
Allen GP. The mutant prevention concentration: a review. Journal of Infectious Diseases Pharmacotherapy 2003;6:27-47.
Allen GP, Cha RC, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 2002;46:2606-12.
Other Scholarly Activity
Allen GP, Black C, Harris KA. Evaluation of in vitro resistance selection in Shigella flexneri by chloramphenicol, gemifloxacin, levofloxacin, pivmecillinam, and rifaximin. Abstract FRIDAY-96. ASM Microbe 2017, New Orleans, LA, June 2017.
Brazeau D, Kim W, Kollar R, Allen G, Vaughn J. Evaluation of RNA preservation buffers for the storage of high quality RNA in clinical and field samples. Abstract SATURDAY-502. ASM Microbe 2017, New Orleans, LA, June 2017.
Brazeau D, Karamchi M, Kollar R, Kim W, Allen G, Vaughn J. Performance evaluation of a liquid amies based medium in detection of the viral and bacterial pathogens using species specific Q-PCR. Abstract TUESDAY-63. ASM Clinical Virology Symposium, Savannah, GA, May 2017.
Allen GP, Harris KA. In vitro evaluation of resistance selection in Shigella flexneri by azithromycin, ceftriaxone, ciprofloxacin, levofloxacin, and moxifloxacin. Abstract SUNDAY-513. ASM Microbe 2016, Boston, MA, June 2016.
Allen GP, Lee JK, Tsui AY, Vo TN. In vitro evaluation of resistance selection by various antimicrobials in Escherichia coli. Abstract A-482. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, September 2015.
Allen GP, Eastman KS, Freudenberger KR. Evaluation of in vitro resistance selection in Shigella flexneri by azithromycin, ceftriaxone, and ciprofloxacin. Abstract A-483. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, September 2015.
Brazeau D, Karamchi M, Kim WE, Allen GP. Performance evaluation of Puritan© Opti-Tranz medium in detection of Bordetella pertussis using real time Q-PCR. Abstract 1087. American Society for Microbiology 115th General Meeting, New Orleans, LA, May-June 2015.
Allen GP, Astrup GE, Dizon JM, McIver LA, Park DY. In vitro evaluation of antimicrobial combinations against fluoroquinolone-resistant Neisseria gonorrhoeae. Abstract A-1331. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, September 2014.
Allen GP, Teklemariam KT, Ton-Nu PD. In vitro evaluation of azithromycin, ceftriaxone, chloramphenicol, ciprofloxacin, ertapenem, fosfomycin, and moxifloxacin against Salmonella enterica serovar Typhi. 4th American Society for Microbiology Conference on Salmonella: The Bacterium, the Host and the Environment, Boston, MA, October 2013.
Allen GP, Paplaskas AM, Malinowski A. In vitro evaluation of antimicrobial combinations against NDM-1 producing Klebsiella pneumoniae. Abstract A-1038. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 2013.
Allen GP, Paplaskas AM, Malinowski A. In vitro evaluation of combinations of colistin and polymyxin B with various antimicrobials against carbapenemase-producing Klebsiella pneumoniae (KPC). Abstract 18. 1st International Conference on Polymyxins, Prato, Italy, May 2013.
Allen GP, Paplaskas AM, Malinowski A. In vitro evaluation of colistin and polymyxin B, alone and in combination with doxycycline, fosfomycin, and tigecycline, against carbapenemase-producing Klebsiella pneumoniae. Abstract B14. The New England Regional Center of Excellence in Biodefense and Emerging Infectious Diseases (NERCE/BEID) 8th Annual Retreat, Newport, RI, November 2012.
Allen GP, Ofodile CC. Evaluation of azithromycin (AZM), ceftriaxone (CRO), and fluoroquinolone (FQ) resistance selection in Salmonella Choleraesuis (SC), S. Paratyphi (SP), and S. Typhimurium (ST). Abstract 126C. 3rd American Society for Microbiology Conference on Antimicrobial Resistance in Zoonotic Bacteria and Foodborne Pathogens, Aix-en-Provence, France, June 2012.
Allen GP, Lakoma LD, Malinowski A. Comparative evaluation of azithromycin (AZM) and clarithromycin (CLR) resistance selection in Salmonella Typhi (ST) using an in vitro pharmacodynamic model (IVPM). Abstract A-037. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 2011.